Search

Corvus Pharmaceuticals Inc

Geschlossen

13.94 0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.54

Max

13.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.4M

-14M

EPS

-0.15

Angestellte

37

EBITDA

312K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+127.99% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-223M

1.1B

Vorheriger Eröffnungskurs

13.36

Vorheriger Schlusskurs

13.94

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2026, 23:56 UTC

MSCI Inc. shares are higher in after-market trading, gaining since Thursday's close despite earlier pulling back from a session high.

6. Aug. 2026, 23:56 UTC

Intercontinental Exchange Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

6. Aug. 2026, 23:56 UTC

General Motors Co. shares remain roughly flat in after-market trading. The stock is near the upper end of its one-month range.

6. Aug. 2026, 23:56 UTC

KeyCorp shares are modestly higher in after-market trading following Thursday's close, with no specific company news identified to explain the price action.

6. Aug. 2026, 23:56 UTC

BWX Technologies shares are higher in after-market hours, following an early spike after the market closed. The stock remains below its 20-day moving average.

6. Aug. 2026, 23:56 UTC

Correlated Moves

Lattice Semiconductor is higher in after-market trading, likely influenced by positive momentum in the semiconductor sector and a significant rise in Microchip Technology's stock.

6. Aug. 2026, 23:56 UTC

Dycom Industries Inc. is trading higher in after-market hours, reflecting a slight gain since Thursday's close, with no specific news identified.

6. Aug. 2026, 23:56 UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

6. Aug. 2026, 23:56 UTC

Tripadvisor Inc shares are higher in after-market trading, reflecting positive sentiment despite broader market challenges. The stock previously peaked before a slight pullback.

6. Aug. 2026, 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

6. Aug. 2026, 23:56 UTC

Correlated Moves

Entergy Corp shares advanced in after-market trading, reflecting a positive trend in the electric utilities sector amid broader market dynamics.

6. Aug. 2026, 23:56 UTC

NRG Energy Inc shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

6. Aug. 2026, 23:56 UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

6. Aug. 2026, 23:56 UTC

iShares iBoxx $ High Yield Corporate Bond ETF traded roughly flat after market hours, with mixed performance in global equity indices and a stronger U.S. Dollar.

6. Aug. 2026, 23:56 UTC

Akebia Therapeutics Inc. shares are higher in after-market trading, advancing modestly since Thursday's close amid routine fluctuations within a narrow range.

6. Aug. 2026, 23:56 UTC

Parker-Hannifin Corp shares are higher in after-market hours, recovering from an earlier dip and reflecting a modest uptick since Thursday's close.

6. Aug. 2026, 23:56 UTC

Magnite Inc. shares are trading lower in after-market hours, with no specific news identified. The stock remains above its 20-day moving average.

6. Aug. 2026, 23:52 UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

6. Aug. 2026, 23:51 UTC

Mosaic Co shares traded roughly flat in after-market hours amid a strengthening U.S. Dollar and rising crude oil prices contributing to market volatility.

6. Aug. 2026, 23:51 UTC

Correlated Moves

Patrick Industries Inc shares are higher in after-market trading, reflecting positive sector sentiment and following gains in SiteOne Landscape Supply Inc.

6. Aug. 2026, 23:51 UTC

VF Corp shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

6. Aug. 2026, 23:51 UTC

Exlservice Holdings Inc shares are higher in after-market trading, continuing a recent upward trend and remaining well above their 20-day moving average.

6. Aug. 2026, 23:51 UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

6. Aug. 2026, 23:51 UTC

Ralph Lauren Corp shares are trading lower in after-market hours. The stock saw notable volatility today amid broader market factors, including a stronger U.S. Dollar.

6. Aug. 2026, 23:51 UTC

Payoneer Global Inc shares are declining in after-market trading, reversing from earlier gains and remaining below the 20-day moving average.

6. Aug. 2026, 23:51 UTC

Conagra Brands Inc shares are higher in after-market hours, reaching a session high and remaining above the 20-day moving average. No specific news was identified.

6. Aug. 2026, 23:51 UTC

Alliant Energy Corp shares advanced during after-market hours, reflecting unusual strength despite being below the 20-day moving average and recent declines.

6. Aug. 2026, 23:51 UTC

UiPath Inc shares are lower in after-market hours following Thursday's close, despite earlier fluctuations. Broader market dynamics may be influencing the decline.

6. Aug. 2026, 23:51 UTC

Greenbrier Companies Inc. shares are lower in after-market trading, continuing a trend of declines over three consecutive sessions amid broader market volatility.

6. Aug. 2026, 23:51 UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

127.99% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD  127.99%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat